245 related articles for article (PubMed ID: 27521306)
21. Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned.
Pinilla-Ibarz J; Sweet KL; Corrales-Yepez GM; Komrokji RS
Onco Targets Ther; 2016; 9():4937-57. PubMed ID: 27570458
[TBL] [Abstract][Full Text] [Related]
22. Ruxolitinib dose management as a key to long-term treatment success.
Mesa RA; Komrokji RS; Verstovsek S
Int J Hematol; 2016 Oct; 104(4):420-9. PubMed ID: 27567907
[TBL] [Abstract][Full Text] [Related]
23. A Review of Ruxolitinib for the Treatment of Myelofibrosis: A Critique of the Evidence.
Wade R; Hodgson R; Biswas M; Harden M; Woolacott N
Pharmacoeconomics; 2017 Feb; 35(2):203-213. PubMed ID: 27592020
[TBL] [Abstract][Full Text] [Related]
24. How to Treat Essential Thrombocythemia and Polycythemia Vera.
Besses C; Alvarez-Larrán A
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S114-23. PubMed ID: 27521307
[TBL] [Abstract][Full Text] [Related]
25. JAK2-mutated Langerhans cell histiocytosis associated with primary myelofibrosis treated with ruxolitinib.
Bonometti A; Bagnoli F; Fanoni D; Venegoni L; Corti L; Bianchi P; Elli EM; Isimbaldi G; L'Imperio V; Nazzaro G; Passoni E; Berti E
Hum Pathol; 2018 Mar; 73():171-175. PubMed ID: 29107666
[TBL] [Abstract][Full Text] [Related]
26. Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis.
Ailawadhi S; Frank RD; Advani P; Swaika A; Temkit M; Menghani R; Sharma M; Meghji Z; Paulus S; Khera N; Hashmi SK; Paulus A; Kakar TS; Hodge DO; Colibaseanu DT; Vizzini MR; Roy V; Colon-Otero G; Chanan-Khan AA
Cancer Med; 2017 Dec; 6(12):2876-2885. PubMed ID: 29105343
[TBL] [Abstract][Full Text] [Related]
27. Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia.
Medeiros BC; McCaul K; Kambhampati S; Pollyea DA; Kumar R; Silverman LR; Kew A; Saini L; Beach CL; Vij R; Wang X; Zhong J; Gale RP
Haematologica; 2018 Jan; 103(1):101-106. PubMed ID: 29097499
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis.
Tefferi A; Lasho TL; Finke C; Gangat N; Hanson CA; Ketterling RP; Pardanani A
Leukemia; 2018 Mar; 32(3):837-839. PubMed ID: 29089644
[No Abstract] [Full Text] [Related]
29. Myelofibrosis: an update on drug therapy in 2016.
Bose P; Verstovsek S
Expert Opin Pharmacother; 2016 Dec; 17(18):2375-2389. PubMed ID: 27774820
[TBL] [Abstract][Full Text] [Related]
30. Circulating Calreticulin Is Increased in Myelofibrosis: Correlation with Interleukin-6 Plasma Levels, Bone Marrow Fibrosis, and Splenomegaly.
Sollazzo D; Forte D; Polverelli N; Perricone M; Romano M; Luatti S; Vianelli N; Cavo M; Palandri F; Catani L
Mediators Inflamm; 2016; 2016():5860657. PubMed ID: 27672242
[TBL] [Abstract][Full Text] [Related]
31. Circulating Cd34+ cell count differentiates primary myelofibrosis from other Philadelphia-negative myeloproliferative neoplasms: a pragmatic study.
Orvain C; Luque Paz D; Dobo I; Cottin L; Le Calvez G; Chauveau A; Mercier M; Farhi J; Boyer F; Ianotto JC; Guibourg B; Rousselet MC; Zandecki M; Ifrah N; Hunault-Berger M; Ugo V; Genevieve F
Ann Hematol; 2016 Oct; 95(11):1819-23. PubMed ID: 27582015
[TBL] [Abstract][Full Text] [Related]
32. How I treat essential thrombocythemia.
Rumi E; Cazzola M
Blood; 2016 Nov; 128(20):2403-2414. PubMed ID: 27561316
[TBL] [Abstract][Full Text] [Related]
33. Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.
Geyer HL; Kosiorek H; Dueck AC; Scherber R; Slot S; Zweegman S; Te Boekhorst PA; Senyak Z; Schouten HC; Sackmann F; Fuentes AK; Hernández-Maraver D; Pahl HL; Griesshammer M; Stegelmann F; Döhner K; Lehmann T; Bonatz K; Reiter A; Boyer F; Etienne G; Ianotto JC; Ranta D; Roy L; Cahn JY; Harrison CN; Radia D; Muxi P; Maldonado N; Besses C; Cervantes F; Johansson PL; Barbui T; Barosi G; Vannucchi AM; Paoli C; Passamonti F; Andreasson B; Ferrari ML; Rambaldi A; Samuelsson J; Cannon K; Birgegard G; Xiao Z; Xu Z; Zhang Y; Sun X; Xu J; Kiladjian JJ; Zhang P; Gale RP; Mesa RA
Haematologica; 2017 Jan; 102(1):85-93. PubMed ID: 27540137
[TBL] [Abstract][Full Text] [Related]
34. The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies.
Gupta V; Harrison C; Hexner EO; Al-Ali HK; Foltz L; Montgomery M; Sun W; Gopalakrishna P; Kantarjian H; Verstovsek S
Haematologica; 2016 Dec; 101(12):e482-e484. PubMed ID: 27587385
[No Abstract] [Full Text] [Related]
35. Prognostic Importance of C-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia: A Systematic Review.
Ayatollahi H; Shajiei A; Sadeghian MH; Sheikhi M; Yazdandoust E; Ghazanfarpour M; Shams SF; Shakeri S
Hematol Oncol Stem Cell Ther; 2017 Mar; 10(1):1-7. PubMed ID: 27613372
[TBL] [Abstract][Full Text] [Related]
36. Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia.
Hirsch P; Zhang Y; Tang R; Joulin V; Boutroux H; Pronier E; Moatti H; Flandrin P; Marzac C; Bories D; Fava F; Mokrani H; Betems A; Lorre F; Favier R; Féger F; Mohty M; Douay L; Legrand O; Bilhou-Nabera C; Louache F; Delhommeau F
Nat Commun; 2016 Aug; 7():12475. PubMed ID: 27534895
[TBL] [Abstract][Full Text] [Related]
37. Current State of the Art: Management of Higher Risk Myelodysplastic Syndromes.
Komrokji RS
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S39-43. PubMed ID: 27521322
[TBL] [Abstract][Full Text] [Related]
38. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.
Vainchenker W; Kralovics R
Blood; 2017 Feb; 129(6):667-679. PubMed ID: 28028029
[TBL] [Abstract][Full Text] [Related]
39. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A; Barbui T
Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
[TBL] [Abstract][Full Text] [Related]
40. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management.
Tefferi A
Am J Hematol; 2018 Dec; 93(12):1551-1560. PubMed ID: 30039550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
